Evidence map›Paper›PMID 29556730›Full record

ArticlePharmaceutical research2018

Impact of Buffer, Protein Concentration and Sucrose Addition on the Aggregation and Particle Formation during Freezing and Thawing.

Astrid Hauptmann, Katja Podgoršek, Drago Kuzman, Stanko Srčič, Georg Hoelzl, Thomas Loerting

Erratum issuedAbstract read
In one paragraph

Article in Pharmaceutical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Study of Oncolytic Virus Preservation and Formulation.Pharmaceuticals (Basel, Switzerland) · 2023
    Review
  10. Article
  11. Article
  12. Article
  13. Solubilization and Refolding of Inclusion Body Proteins.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Astrid HauptmannInstitute of Physical Chemistry, University of Innsbruck, Innrain 52c, 6020, Innsbruck, Austria.
Katja PodgoršekLek Mengeš, 1234, Mengeš, Slovenia.
Drago KuzmanLek Mengeš, 1234, Mengeš, Slovenia.
Stanko SrčičFaculty of Pharmacy, University of Ljubljana, 1000, Ljubljana, Slovenia.
Georg HoelzlSandoz GmbH, 6336, Langkampfen, Austria.
Thomas LoertingInstitute of Physical Chemistry, University of Innsbruck, Innrain 52c, 6020, Innsbruck, Austria. thomas.loerting@uibk.ac.at.

Funding

Austrian Science Fund I1392
6 · The paper itself

Abstract

purposeThis study addresses the effect of freezing and thawing on a therapeutic monoclonal antibody (mAb) solution and the corresponding buffer formulation. Particle formation, crystallization behaviour, morphology changes and cryo-concentration effects were studied after varying the freezing and thawing rates, buffer formulation and protein concentration. The impact of undergoing multiple freeze/thaw (FT)-cycles at controlled and uncontrolled temperature rates on mAb solutions was investigated in terms of particle formation.

methodsPhysicochemical characteristics were analysed by Differential Scanning Calorimetry whereas morphology changes are visualized by cryomicroscopy measurements. Micro Flow Imaging, Archimedes and Dynamic Light Scattering were used to investigate particle formation.

resultsData retrieved in the present study emphasizes the damage caused by multiple FT-cyles and the need for sucrose as a cryoprotectant preventing cold-crystallization specifically at high protein concentrations. Low protein concentrations cause an increase of micron particle formation. Low freezing rates lead to a decreased particle number with increased particle diameter.

conclusionThe overall goal of this research is to gain a better understanding of the freezing and thawing behaviour of mAb solutions with the ultimate aim to optimize this process step by reducing the unwanted particle formation, which also includes protein aggregates.

Indexed as

Protein AggregatesAntibodies, MonoclonalBuffersCalorimetry, Differential ScanningChemistry, PharmaceuticalCrystallizationDrug CompoundingDrug StabilityDrug StorageFreezingImmunologic FactorsProtein StabilitySucroseAntibodies, MonoclonalBuffersImmunologic FactorsProtein AggregatesSucrosebuffer and mAb formulationcryomicroscopyfreezingparticle formationthawing

Identifiers

PMID29556730
PMCPMC5859698

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.